Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIVI BioVie	$1.07 -7.0%	$0.96	$0.62 ▼ $7.50	$19.74M	0.66	596,901 shs	472,399 shs
CLLS Cellectis	$1.41 -6.6%	$1.37	$1.10 ▼ $3.10	$78.37M	3.11	141,706 shs	52,790 shs
CLYM Climb Bio	$1.27 +2.4%	$1.27	$1.05 ▼ $9.58	$85.82M	-0.12	294,852 shs	71,872 shs
ZURA Zura Bio	$1.21 -2.4%	$1.28	$0.97 ▼ $6.35	$82.73M	0.05	392,477 shs	181,404 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIVI BioVie	+3.14%	+0.88%	+47.44%	-36.11%	+136.53%
CLLS Cellectis	-5.63%	-5.63%	+4.86%	-0.13%	-50.65%
CLYM Climb Bio	+4.20%	-0.80%	-3.13%	-20.00%	+123,999,900.00%
ZURA Zura Bio	+2.48%	-13.89%	+2.48%	-12.06%	-73.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIVI BioVie	3.0751 of 5 stars	3.8	4.0	4.2	0.0	0.6
CLLS Cellectis	3.2057 of 5 stars	3.5	5.0	2.1	2.5	0.6
CLYM Climb Bio	3.1243 of 5 stars	3.8	0.0	2.7	2.5	1.3
ZURA Zura Bio	2.5168 of 5 stars	3.6	3.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIVI BioVie	3.50	Strong Buy	$3.00	180.37% Upside
CLLS Cellectis	3.00	Buy	$6.67	372.81% Upside
CLYM Climb Bio	3.50	Strong Buy	$10.00	687.40% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,084.57% Upside

Current Analyst Ratings Breakdown

Latest BIVI, ZURA, CLLS, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/18/2025	BIVI BioVie	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIVI BioVie	N/A	N/A	N/A	N/A	$2.54 per share	N/A
CLLS Cellectis	$41.51M	1.89	N/A	N/A	$1.52 per share	0.93
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.90 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIVI BioVie	-$32.12M	-$9.76	N/A	∞	N/A	N/A	-134.07%	-93.44%	5/13/2025 (Estimated)
CLLS Cellectis	-$101.06M	-$0.83	N/A	N/A	N/A	-234.39%	-74.55%	-22.65%	N/A
CLYM Climb Bio	-$35.12M	-$2.13	N/A	N/A	N/A	N/A	-42.21%	-41.39%	5/21/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.70	N/A	N/A	N/A	N/A	-37.36%	-29.81%	N/A

Latest BIVI, ZURA, CLLS, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CLYM Climb Bio	-$0.15	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q3 2025	BIVI BioVie	-$0.32	-$0.15	+$0.17	-$0.15	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/25/2025	Q4 2024	CLYM Climb Bio	-$0.15	-$0.13	+$0.02	-$0.13	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million
3/13/2025	Q4 2024	CLLS Cellectis	$0.06	-$0.16	-$0.22	-$0.15	$5.90 million	$33.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIVI BioVie	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIVI BioVie	N/A	16.94	16.94
CLLS Cellectis	0.48	1.78	1.78
CLYM Climb Bio	N/A	57.73	57.73
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIVI BioVie	4.59%
CLLS Cellectis	63.90%
CLYM Climb Bio	69.76%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
BIVI BioVie	4.00%
CLLS Cellectis	16.41%
CLYM Climb Bio	0.80%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIVI BioVie	10	18.45 million	17.71 million	No Data
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
CLYM Climb Bio	9	67.58 million	65.07 million	N/A
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

BIVI, ZURA, CLLS, and CLYM Headlines

Recent News About These Companies

Oppenheimer Cuts Zura Bio (NASDAQ:ZURA) Price Target to $17.00

May 12 at 1:22 AM | americanbankingnews.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

Boxer Capital Management LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)

May 4, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives $14.67 Consensus PT from Brokerages

May 4, 2025 | americanbankingnews.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Buys Shares of 300,000 Zura Bio Limited (NASDAQ:ZURA)

May 2, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Analysts

May 1, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in April

April 30, 2025 | marketbeat.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

JPMorgan Chase & Co. Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

April 20, 2025 | marketbeat.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
2 Smart Investments to Follow Warren Buffett’s Lead
By Ryan Hasson | April 23, 2025
View 2 Smart Investments to Follow Warren Buffett’s Lead
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
By Jeffrey Neal Johnson | April 22, 2025
View Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

BIVI, ZURA, CLLS, and CLYM Company Descriptions

BioVie NASDAQ:BIVI

$1.07 -0.08 (-6.96%)

As of 04:00 PM Eastern

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Cellectis NASDAQ:CLLS

$1.41 -0.10 (-6.62%)

As of 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Climb Bio NASDAQ:CLYM

$1.27 +0.03 (+2.42%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Zura Bio NASDAQ:ZURA

$1.21 -0.03 (-2.42%)

As of 04:00 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time